Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.50 |
| ▸ | CA2 | P00918 | 11/20 | 0.50 |
| ▸ | CA9 | Q16790 | 9/20 | 0.50 |
| ▸ | CA4 | P22748 | 8/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA6 | P23280 | 7/20 | 0.50 |
| ▸ | CA5A | P35218 | 7/20 | 0.50 |
| ▸ | CA7 | P43166 | 7/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781004 | 0.83 | CA2 (0.50) | CA1CA2CA9CA4CA12 | |
| SCHEMBL6939253 | 0.81 | CTDSP1 (0.42) | CA1CA2CA9CA4CA12 | |
| SCHEMBL31095544 | 0.77 | CA2 (0.54) | CA1CA2CA9CA4CA12 | |
| SCHEMBL393315 | 0.77 | CA2 (0.54) | CA1CA2CA9CA4CA12 | |
| SCHEMBL30016544 | 0.77 | CA1 (0.48) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18688250 | 0.77 | TET2 (0.50) | CA1CA2CA9CA4CA12 | |
| SCHEMBL1807656 | 0.76 | CA2 (0.63) | CA1CA2CA9CA4CA12 | |
| SCHEMBL2778211 | 0.74 | CA12 (0.50) | CA1CA2CA9CA4CA12 | |
| SCHEMBL2131504 | 0.74 | CA1 (0.55) | CA1CA2CA9CA4CA12 | |
| SCHEMBL30885712 | 0.74 | CA12 (0.50) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359548-A | Preparation method of benzodiazepine compound | 重庆医科大学 | 2024-07-19 | — | — | CN | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9156832-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S. | 2004-03-04 | — | — | US | disclosed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| CN-1081633-C | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 2002-03-27 | — | — | CN | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
| CN-1293665-A | New compounds and their use as positive AMPA receptor modulators | NEUROSEARCH AS (DK) | 2001-05-02 | — | — | CN | disclosed |
| EP-1071426-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999042456-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-26 | — | — | WO | disclosed |
| CN-1222910-A | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 1999-07-14 | — | — | CN | disclosed |
| EP-0906297-A1 | 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997049692-A1 | 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | CA1 3478/4885CA2 4004/4885CA9 4651/4885 |
| US-20040043987-A1 | Novel compounds and their use as positive AMPA receptor modulators | GRIK4, GRIA4, GRM2 | CA1 388/4885CA2 365/4885CA9 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.